NAD+ marketing has become one of the FTC’s 2024-2026 enforcement focus areas. The agency has publicly flagged anti-aging, cognitive-enhancement, and longevity claims in the supplement and wellness space as a priority, and NAD+ marketing combines all three claim categories in ways that make it an obvious enforcement target. If you run an IV therapy clinic, wellness practice, or concierge medicine clinic offering NAD+ services, your current marketing almost certainly contains phrases the FTC is actively pursuing.
This post walks through what NAD+ actually is (for regulatory purposes), why it’s specifically in FTC focus, the claim categories currently under enforcement, and compliant framings that preserve marketing effectiveness without triggering the specific patterns regulators target.
What NAD+ is, in regulatory terms
NAD+ (nicotinamide adenine dinucleotide) is a coenzyme present in every cell, involved in cellular energy metabolism and DNA repair processes. The underlying biology is genuine. The regulatory question is not about NAD+’s existence or its biological role - it’s about what specific claims about outcomes in humans are supported by adequate and reliable evidence.
NAD+ products in the clinical context take several forms:
- NAD+ IV infusions. Typically prepared as compounded formulations by licensed compounding pharmacies and administered by healthcare practices.
- NAD+ subcutaneous injections. Lower-dose alternatives to IV administration.
- NAD+ precursor supplements (NR, NMN).Dietary supplements marketed with structure-function claims under DSHEA.
- NAD+ precursor combined protocols. IV combined with supplement maintenance.
The marketing issues are most acute for the injectable forms (IV and SQ) because they are legally prescription preparations and the advertising falls under the prescription-drug advertising framework rather than the supplement framework.
Why the FTC is focused on this specifically
Three factors make NAD+ an enforcement priority:
Factor 1: Aggressive consumer claims
NAD+ marketing routinely makes sweeping claims - “reverses aging,” “extends lifespan,” “boosts cognition by X%,” “restores cellular function.” The claims are both specific enough to trigger substantiation requirements and ambitious enough to make the evidentiary gap obvious.
Factor 2: Weak clinical evidence on outcomes
The human clinical evidence for many specific marketed outcomes is thin - small studies, short durations, mixed results, limited blinding. Whatever one’s view of the underlying biology, the clinical evidence does not meet the FTC’s competent-and-reliable standard for many common claims.
Factor 3: Vulnerable consumer target
NAD+ marketing frequently targets older consumers concerned about cognitive decline, cancer patients, and patients with chronic illness. The FTC applies heightened scrutiny to marketing targeting populations that are particularly vulnerable to misleading health claims.
The specific claim patterns under enforcement
Pattern 1: Anti-aging reversal claims
“Our NAD+ IV therapy reverses the aging process at the cellular level.”
“NAD+ is a coenzyme involved in cellular energy metabolism. Some patients report subjective improvements in energy and well-being after treatment; individual experiences vary, and research into NAD+ biology continues.”
Why: 'Reverses aging' is a top-priority FTC enforcement target. Compliant framing describes what NAD+ is and what patients report without claiming biological reversal of aging.
Pattern 2: Cognitive enhancement specifics
“Improves memory, focus, and cognitive function - many patients report mental clarity within a single session.”
“Some patients describe subjective feelings of mental clarity and energy following treatment; these responses vary widely by individual and do not represent clinical evidence of cognitive enhancement.”
Why: Cognitive-enhancement claims trigger both FTC substantiation rules and FDA disease-claim rules (cognitive decline is a medical diagnosis). Subjective-report framing avoids the claim while preserving the marketing message.
Pattern 3: Longevity / lifespan extension
“NAD+ supports longevity - studies show it may extend lifespan by up to 30%.”
“Research on NAD+ biology, including cellular and animal studies, continues to evolve. We do not make specific claims about lifespan extension in humans, as that level of evidence does not currently exist.”
Why: Lifespan-extension claims require human clinical evidence over years or decades - which does not exist for any current NAD+ protocol. Citing cellular or animal studies to support human lifespan claims is a specific enforcement pattern.
Pattern 4: Chronic fatigue and disease-adjacent claims
“NAD+ therapy cures chronic fatigue syndrome and brain fog.”
“Some patients with fatigue or post-viral symptoms report subjective improvement with NAD+ treatment as part of a broader care plan; our medical team discusses whether this is clinically appropriate for each patient.”
Why: 'Cures chronic fatigue syndrome' is a disease-treatment claim for a diagnosable medical condition. Subjective-improvement framing with provider-gated language avoids the disease claim.
Pattern 5: Cancer-recovery or chemotherapy support
“Our NAD+ protocol supports cancer patients through chemotherapy recovery.”
“[Remove entirely. Do not include this indication in public marketing without specific clinical evidence and attorney review. Cancer-related claims face the highest FTC scrutiny and the highest FDA enforcement risk.]”
Why: Cancer-related marketing is the highest-risk healthcare marketing category. Even framings like 'supports' can cross into treatment claim territory. This is one of a small number of indications where the safest approach is to simply not market it.
Pattern 6: Celebrity/testimonial-driven marketing
“[Celebrity] swears by our NAD+ protocol - you can too!”
“[Remove unless documented paid endorsement with FTC-compliant material-connection disclosure in the post itself.]”
Why: Celebrity implied endorsement without proper disclosure is a top-5 FTC enforcement pattern. NAD+ is a space where celebrity mentions appear frequently in clinic marketing, often without the required disclosures.
What compliant NAD+ marketing looks like
Lead with biology, not outcomes
“NAD+ is a coenzyme present in every cell, involved in cellular energy metabolism and DNA repair processes. Research into its biology and clinical applications continues to evolve.” This is factually accurate, informative, and sets expectations without making specific outcome claims.
Describe the service honestly
“Our NAD+ infusion sessions are administered by licensed medical staff using compounded preparations from a licensed compounding pharmacy. Sessions typically take 2-4 hours depending on dose and individual tolerance.” Specific, factual, does not overclaim.
Frame patient reports as subjective
“Some patients describe subjective improvements in energy, mental clarity, or overall well-being following treatment. Individual experiences vary significantly, and these reports do not constitute clinical evidence of specific outcomes.” This captures the actual marketing message (patients often feel good) without claiming clinical effects.
Acknowledge the evidence state
“The clinical evidence for specific outcomes of NAD+ therapy in humans is still developing. We offer this service to patients interested in exploring NAD+ as part of a broader wellness approach, with a clear understanding that it is not an established treatment for any specific medical condition.” This is genuinely honest and defensibly compliant.
Keep disease-specific indications out of public marketing
Cancer, Parkinson’s, Alzheimer’s, ALS, post-viral illness, chronic fatigue syndrome, fibromyalgia - keep these out of public marketing even when clinical discussion may appropriately include them. The in-consultation conversation and the public marketing operate under different rules.
The supplement layer (NR, NMN)
If your practice also sells NAD+ precursor supplements (NR, NMN), those operate under DSHEA - dietary supplement rules. Structure-function claims (“supports cellular energy”) are permitted with the required DSHEA disclaimer and adequate substantiation. Disease claims (same list: cures, treats, prevents) are not permitted in either framework. The supplement layer does not cure compliance issues in the IV or injection layer - they’re independent.
Frequently asked questions
Can I cite studies on NAD+ biology in my marketing?
Citing studies accurately is generally fine. The issue is how the citations are used. A study on NAD+ in cells or in animals cited to support a claim about human outcomes is a substantiation mismatch - the evidence doesn’t reach the claim. Citing studies to support what you’re actually doing (“research on NAD+ biology continues”) is fine.
What about IV drips combining NAD+ with other ingredients?
Combination infusions face the same rules plus complexity from the additional ingredients. Each claim needs substantiation tied to what’s actually in the infusion. Generic “wellness boost” framing is easier to defend than specific outcome claims.
Is NAD+ FDA-approved for anything?
Nicotinamide (vitamin B3) is an approved drug for certain medical indications. NAD+ as administered in most wellness and IV therapy contexts is not FDA-approved for the marketed indications. The distinction matters for marketing language.
What about research/clinical trial framing?
Genuine clinical trials operating under an IND can discuss research purposes within the scope of the IND. A wellness clinic offering NAD+ as a service is not conducting an IND clinical trial, and framing services as research when they aren’t creates an additional misrepresentation.
Can I show patient “before/after” energy-level testimonials?
Yes, with proper FTC endorsement framing - typical- experience disclosure, material-connection disclosure if applicable, and avoidance of disease-related outcome framing. Energy and well-being testimonials are lower-risk than disease-specific testimonials because they don’t directly imply disease treatment.
What about longevity physicians with NAD+ in their protocols?
Longevity-medicine practices face the same rules, often more stringently because the entire practice is marketed around longevity outcomes. The practice-level marketing needs the same compliance treatment as the individual service-level marketing. “Longevity medicine” framing itself is increasingly drawing FTC attention when paired with specific outcome claims.